New approach to the localisation of phaeochromocytoma: imaging with iodine-131-meta-iodobenzylguanidine.
D. M. AckeryWessex Regional Department of Nuclear Medicine, Chemical Path-ology, and Human Metabolism, and Department of Chemistry, University of Southampton DUNCAN M ACKERY, MB, MSC, consultant in nuclear medicinePatricia TippettWessex Regional Department of Nuclear Medicine, Southampton General Hospital, Southampton S09 4XY. 1587Barrie CondonWessex Regional Department of Nuclear Medicine, Chemical Path-ology, and Human Metabolism, and Department of Chemistry, University of Southampton DUNCAN M ACKERY, MB, MSC, consultant in nuclear medicineH. Eldon Sutton, consultant in nuclear medicinePaul WyethWessex Regional Department of Nuclear Medicine , Chemical Path- ology, and Human Metabolism , and Department of Chemistry , University of Southampton
1984en
Ochiq kirishBronza
ABI
Annotatsiya
Thirty eight patients with known or suspected phaeochromocytoma were studied by radioisotope imaging after intravenous administration of iodine-131-meta- iodobenzylguanidine (131I- mIBG ), a radiopharmaceutical which has affinity for chromaffin tumours. Seventeen positive results (including one false positive) and 21 negative results (including two false negatives) were obtained. Clinical accuracy was 92%. Urinary noradrenaline concentrations were raised in all patients with confirmed phaeochromocytoma. These findings show that 131I- mIBG is of value in localising and assessing the extent of chromaffin tumours.
Hali tarjima qilinmagan
Identifikatorlar
Iqtiboslar va manbalar
0 ta iqtibos32 ta foydalanilgan manba